Antibody producing human-human hybridomas. I. Technical aspects.

Area of Science:

• Immunotechnology
• Cell Biology
• Hybridoma Technology

Background:

• Human-human hybridoma technology is crucial for producing monoclonal antibodies for therapeutic and diagnostic applications.
• Challenges exist in efficiently generating stable, antibody-secreting human hybridomas compared to murine systems.

Purpose of the Study:

• To evaluate technical aspects of generating human-human hybridomas using specific fusion partners.
• To compare human hybridoma production with established mouse hybridoma systems.
• To identify strategies for improving the yield and stability of human hybridomas.

Main Methods:

• Performed 100 human-human hybridoma fusions using B-lymphoma (RH-L4) or myeloma (SKO-007) cell lines as fusion partners.
• Compared fusion efficiency using peripheral blood lymphocytes versus spleen lymphocytes.
• Investigated the effect of mitogen stimulation of lymphocytes prior to fusion, particularly in HAT medium.
• Assessed hybridoma growth rate and chromosomal stability post-fusion.

Main Results:

• Significantly lower hybridoma yield was observed with peripheral blood lymphocytes compared to spleen lymphocytes.
• Mitogen stimulation of lymphocytes, especially in HAT medium, substantially increased the number of mitotic B-lymphocytes and improved hybrid yield.
• Human hybridomas exhibited slower growth and higher chromosomal instability than typical mouse hybridomas.
• Only 3 stable, antibody-producing human hybrids were established from 72 fusions.

Conclusions:

• Optimizing the source and preparation of human B-lymphocytes is critical for successful human hybridoma production.
• Current methods result in lower yields and stability of human hybridomas compared to mouse models.
• Further research into improving human B-lymphocyte sources and fusion techniques is warranted for advancing human hybridoma technology.